During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

Bristol Myers Squibb (NYSE:BMY) said that ongoing initiatives to cut costs will lead to the realization of $1.5B in annual ...

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...

It was also confirmed that HDCA inhibited the Epiregulin (EREG)/Epidermal Growth Factor Receptor (EGFR) pathway by activating FXR, and a negative correlation between FXR and EREG was analyzed in CRC ...

Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610065, China Targeted Tracer ...

肺癌的主要亚型非小细胞肺腺癌有比较大的概率可以靶向治疗，对于亚裔的非小细胞肺腺癌患者来说，EGFR基因突变概率非常高，可以达到50%的突变 ...